California State Teachers Retirement System Sells 35,997 Shares of NxStage Medical, Inc. (NASDAQ:NXTM)

California State Teachers Retirement System decreased its holdings in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 25.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 103,218 shares of the medical device company’s stock after selling 35,997 shares during the period. California State Teachers Retirement System owned approximately 0.15% of NxStage Medical worth $2,954,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NXTM. Kite Lake Capital Management UK LLP lifted its stake in NxStage Medical by 228.3% in the third quarter. Kite Lake Capital Management UK LLP now owns 1,151,980 shares of the medical device company’s stock valued at $32,128,000 after acquiring an additional 801,048 shares during the last quarter. JPMorgan Chase & Co. increased its position in NxStage Medical by 56.3% during the third quarter. JPMorgan Chase & Co. now owns 1,187,250 shares of the medical device company’s stock worth $33,113,000 after acquiring an additional 427,745 shares during the period. Manikay Partners LLC bought a new position in NxStage Medical during the third quarter worth about $11,853,000. Canada Pension Plan Investment Board bought a new position in NxStage Medical during the third quarter worth about $7,792,000. Finally, Marshall Wace LLP increased its position in NxStage Medical by 31.4% during the third quarter. Marshall Wace LLP now owns 1,148,542 shares of the medical device company’s stock worth $32,033,000 after acquiring an additional 274,664 shares during the period. Institutional investors own 80.34% of the company’s stock.

NASDAQ:NXTM remained flat at $$30.00 during mid-day trading on Wednesday. 2,608,346 shares of the company were exchanged, compared to its average volume of 1,506,712. NxStage Medical, Inc. has a 1-year low of $23.17 and a 1-year high of $30.00. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -136.36 and a beta of 0.25.

NXTM has been the topic of a number of recent research reports. BidaskClub lowered shares of NxStage Medical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 22nd. Zacks Investment Research lowered shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Saturday, February 9th.

ILLEGAL ACTIVITY NOTICE: This report was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/california-state-teachers-retirement-system-trims-stake-in-nxstage-medical-inc-nxtm.html.

NxStage Medical Company Profile

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

See Also: What are popular green investing opportunities?

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.